Option chain shows key data for Ryde Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ryde Group.

Ryde Group (AMEX:RYDE) Stock, Option Chain

Ryde Group

Ryde Group Ltd is a company providing a super mobility app offering ultimate convenience and reliability for their customers through multiple mobility tools that can be accessed and function seamlessly out of a single app. The company operates in the following segments such as being mobility where it provides on-demand and scheduled carpooling and ride-hailing services, matching riders to driver partners; and quick commerce where it provides on-demand, scheduled, and multi-stop parcel delivery services.

Prague,cz,-27,April,2023:,Logo,On,Accenture,Headquarters,In,Prague.

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

CNXC

KTTA

MDXH

RYDE

TBIO

Dow Surges Over 250 Points; Accenture Earnings Top Views

Crude-oil-4-logo

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Intraday Update

ADPT

Crude Oil Down Over 2%; US Initial Jobless Claims Fall

Wall Street

VSME

Nasdaq Gains Over 1%; Micron Posts Upbeat Q4 Results

Ryde Group Ltd

Ryder System Inc

WIIM

TZUP

Thumpzup Media shares are trading higher after the company announced its ad-tech platform has attracted over 500 advertisers.

Shares of The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) are blasting off on Friday. <a href="https://www.benzinga.com/markets/equities/24/11/42134097/gap-stock-surges-14-in-friday-pre-market-after-boosting-sales-forecast">The company reported earnings of 72 cents a share</a>. This was ahead of estimates of 58 cents.
Some traders are curious as to whether or not a new trading range will form. They will be focused on two important price levels. This is why our team of technical analysts has made Gap our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
If Gap moves higher, there is a good chance that it will run into resistance around the $29.10 level. In the financial markets, there tends to be resistance at levels that were previously peaks. And as you can see on the chart, this level was a peak in May.
This is due to psychology.
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42130782/amazon-at-risk-of-major-fine-as-eu-investigates-alleged-preference-for-in-house-products-under-digital-markets-act-report">Amazon At Risk Of Major Fine As EU Investigates Alleged Preference For In-House Products Under Digital Markets Act: Report</a>
There are traders who purchased shares at the peak that now regret doing so because the price is lower and they are looking at losses. If the shares rally back to their buying price, they will place sell orders so they can get out of their positions at breakeven. If there are enough of these orders, it will create resistance at the same level.
If the stock heads lower, there is a chance there is support around $24.80. As you can see on the chart below, this level was also a peak. And there tends to be support at levels that were peaks.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart-1024x526.png" alt="Gap" class="wp-image-661215" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart-1536x789.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22105450/Gap_chart.png 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Some who sold there regret doing so now that the price is higher. They experience ‘seller's remorse'. Some decide to buy their shares back if they can do so at the same price they were sold for. If there are enough of these buy orders, the level that had been a peak can turn into support.
The long-term picture for Gap seems to be bullish. CEO Richard Dickson said the company&#8217;s performance year-to-date &#8220;gives us the confidence to raise our full-year outlook for sales, gross margin, and operating income growth.&#8221;
But in the short run, traders will be watching these levels to see if they form the resistance and support of a new trading range.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs">Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound</a></li>
</ul>
Image: Wikimedia Commons

Technicals

Stock Of The Day: The Gap Gaps Higher, Will Likely Run Into Resistance At This Level

U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday.
Shares of Natural Grocers by Vitamin Cottage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NYSE">NGVC</a>) rose sharply during Friday's session <a href="https://www.benzinga.com/quote/NGVC/earnings">following quarterly results.</a>
Natural Grocers reported quarterly earnings of 39 cents per share, representing a 50% increase over earnings of 26 cents per share from the same period last year. The company reported $322.66 million in sales this quarter.
Natural Grocers by Vitamin Cottage shares jumped 15.3% to $41.78 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares jumped 41.5% to $15.64 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares surged 26.4% to $9.75.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) jumped 20.6% to $2.3750 after the company issued expectations for quarter-over-quarter fourth-quarter revenue growth.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 18.8% to $2.4000.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) gained 16.6% to $109.82 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) surged 16.6% to $29.74 following upbeat earnings.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 16.2% to $7.48.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) gained 14.3% to $9.52.</li>
<li>Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) jumped 12.3% to $46.81.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 10.7% to $32.90.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares rose 10.66% to $7.72.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares jumped 9.1% to $1.2000</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) gained 8.6% to $92.44. </li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) jumped 6% to $23.35 following upbeat earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) gained 5.3% to $190.29 JP Morgan analyst Bennett Moore initiated coverage on Carpenter Tech with an Overweight rating and announced a price target of $220.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Movers

ATKR

ESTC

MATW

NGVC

NVTS

OMER

PSNY

PTGX

QBTS

REPL

SMCI

SOUN

VSAT

WOLF

Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday

Piper Sandler analyst Kashy Harrison maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Neutral and lowers the price target from $85 to $70.

Price Target

Analyst Ratings

ENPH

Piper Sandler Maintains Neutral on Enphase Energy, Lowers Price Target to $70

UGI shares are trading higher after the company reported better-than-expected FY24 adjusted EPS results.

RBC Capital analyst Elvira Scotto reiterates USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) with a Sector Perform and maintains $27 price target.

Reiteration

USAC

RBC Capital Reiterates Sector Perform on USA Compression Partners, Maintains $27 Price Target

The U.S. private sector activity posted its fastest pace of expansion in more than two and a half years in November, driven by exceptional growth in the services sector, which continues to far exceed even the most <a href="https://www.benzinga.com/news/econ-s">optimistic forecasts by economists.</a>
Business sentiment indicators in both the services and manufacturing sectors, as measured by S&amp;P Global&#8217;s Purchasing Managers&#8217; Index (PMI), improved in November. The services sector recorded its strongest growth since March 2022, while manufacturing saw a slower pace of contraction.
<h3 class="wp-block-heading">US November S&amp;P Global&#8217;s PMI Report: Key Highlights</h3>
<ul>
<li>The Flash Composite PMI rose from 54.1 in October to 55.3 in November, marking the strongest growth since April 2022. </li>
<li>The Flash Services PMI also soared from 55 to 57, surpassing estimates of 57.2 as tracked by TradingEconomics. </li>
<li>The Flash Manufacturing PMI inched up from 48.5 to 48.8, matching expectations. </li>
<li>Companies&#8217; outlook for the year ahead rose to their highest levels since May 2022, fueled by optimism over potential interest rate cuts, stronger economic growth, and more favorable business policies anticipated by the new administration in 2025.</li>
<li>Employment declined for the fourth consecutive month, while output price inflation eased to its lowest level since June 2020.</li>
<li>While growth remained concentrated in the services sector, increased optimism and renewed hiring in manufacturing signaled the potential for a broader recovery in the months ahead.</li>
</ul>
&#8220;The rise in the headline flash PMI indicates that economic growth is accelerating in the fourth quarter, while at the same time inflationary pressures are cooling,&#8221; said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence.
According to Williamson, the survey&#8217;s price index for goods and services suggests that consumer inflation is running significantly below the Federal Reserve&#8217;s 2% target.
Williamson also highlighted the increasing optimism for next-year output from goods-producing businesses. &#8220;The promise of greater protectionism and tariffs has helped lift confidence in the U.S. good producing sector, which is already feeding through to higher factory employment,&#8221; he said.
<h3 class="wp-block-heading">Market reactions: Stocks rise, dollar holds at 2-year highs</h3>
A new round of strong economic data fueled a rally in U.S. stocks, particularly among those most sensitive to domestic economic momentum.
Small-cap stocks, tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), rallied 1.2% on Friday, aiming for their fifth consecutive session of gains.
Blue-chip stocks also posted solid performances, with the Dow Jones, represented by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), climbing 0.5% and surpassing the 44,000 mark.
The U.S. dollar index (DXY), tracked via the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), held steady with a 0.6% gain after touching fresh two-year highs<a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs"> earlier in the session.</a>
Meanwhile, Treasury yields remained flat, and gold advanced 1.1%, also targeting its fifth straight session of gains.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios">2025 US Economy Outlook &#8216;Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

PowerShares DB US Dollar Index Bullish Fund

US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000

Piper Sandler analyst Kashy Harrison maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and raises the price target from $20 to $30.

Piper Sandler Maintains Overweight on Bloom Energy, Raises Price Target to $30

Piper Sandler analyst Adam Butler assumes TFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFSL#NASDAQ">TFSL</a>) with a Neutral rating and announces Price Target of $15.

Initiation

TFSL

Piper Sandler Assumes TFS Financial at Neutral, Announces Price Target of $15

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are trading lower by 10% to $25.13 in November and are near <a href="https://www.benzinga.com/general/biotech/24/11/42015727/stock-of-the-day-is-pfizer-set-up-to-rally">decade-lows</a> after President-elect Donald Trump last week <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">announced his intention</a> to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS).
The decision has heightened concerns over potential policy shifts in vaccine regulation and pharmaceutical oversight, areas central to Pfizer's business.
What To Know: Kennedy, a known vaccine skeptic, has previously promoted discredited theories <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill">linking vaccines to autism</a>. His appointment raises questions about the direction of U.S. health policy under Trump's administration, particularly regarding vaccine guidelines and FDA regulatory practices. 
Pfizer, a global leader in vaccine development with products like the Prevnar pneumonia vaccine and its groundbreaking COVID-19 vaccine, could face new challenges if Kennedy's policies alter vaccine recommendations or erode public trust.
Read Also: <a href="https://www.benzinga.com/24/11/42119511/eli-lilly-stock-tumbles-as-rfk-jr-targets-weight-loss-drugs-buying-opportunity">Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs</a>
In addition to vaccines, Pfizer's broader pharmaceutical operations, including its oncology, rare disease and cardiovascular drug segments, may also be affected by changes in FDA approval processes or drug pricing strategies under Kennedy's tenure. His criticism of pharmaceutical companies' influence over public health has fueled speculation about potential reforms targeting industry practices.
Analysts warn that any major shifts in <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">vaccine policy</a> or regulatory frameworks could have far-reaching consequences for the pharmaceutical sector, with Pfizer among the most exposed.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous">Robert Kennedy Jr. Poised To Lead Health And Human Services: Why FDA, NIH Officials Are Nervous</a>
<h2 class="wp-block-heading">How To Buy PFE Stock</h2>
By now you're likely curious about how to participate in the market for Pfizer &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PFE has a 52-week high of $31.54 and a 52-week low of $24.48.

Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination

Piper Sandler analyst Kashy Harrison downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Overweight to Neutral and lowers the price target from $23 to $11.

Downgrades

Piper Sandler Downgrades Sunrun to Neutral, Lowers Price Target to $11

<a href="https://www.hollywoodreporter.com/movies/movie-features/wicked-box-office-gladiator-previews-1236069327/">https://www.hollywoodreporter.com/movies/movie-features/wicked-box-office-gladiator-previews-1236069327/</a>
Call it whatever you want &mdash; Glicked, Wikiator or Barbienheimer 2.0. The only thing that matters is that the domestic <a href="https://www.hollywoodreporter.com/t/box-office/">box office</a> is <a href="https://www.hollywoodreporter.com/movies/movie-news/moana-2-tracking-record-thanksgiving-opening-1236055787/">springing back to life in historic fashio</a>n thanks to the combo of Universal&#39;s musical <a href="https://www.hollywoodreporter.com/t/wicked/">Wicked</a> and Paramount&#39;s <a href="https://www.hollywoodreporter.com/t/gladiator-ii/">Gladiator II</a>.
Fueled largely by females, Wicked grossed a huge $11 million in Thursday previews from 3,3000 cinemas for a total preview tally of $19.2 million when factoring in special advance screenings held over the past week. On Monday, Amazon Prime screenings generated $2.5 million at 750 theaters, while advance screenings on Wednesday generated another $5.7 million from 2,000 theaters.
Filmmaker Jon M. Chu&#39;s adaptation of the popular Broadway musical boasts a high-profile cast led by <a href="https://www.hollywoodreporter.com/t/ariana-grande/">Ariana Grande</a> and Cynthia Erivo, and should score one of the top opening of all time for a musical, and particularly a live-action musical (think anywhere from $85 million to $150 million). That&#39;s good news for the genre, which has a decidedly mixed record. It&#39;s also good news for Universal, which took a major gamble in making two movies. Wicked II hits theaters a year from now.
The $150 film was originally set to open Nov. 27, the day before Thanksgiving, but moved up to build word of mouth heading into Thanksgiving week. The new date also allows gives it some breathing room from Disney&#39;s <a href="https://www.hollywoodreporter.com/t/moana-2/">Moana 2</a>, which sails into theaters on the 27th. Moana 2 is likewise looking like a monster and is expected to lead the biggest five-day holiday weekend of all time (Wednesday through Sunday).
Social media has been abuzz with speculation that Gladiator II and Wicked will replicate the Barbenheimer effect this weekend and be the perfect pairing in terms of attracting males and females to the multiplex. Wicked presently boasts an 89 percent fresh ratings critics score on Rotten Tomatoes and Gladiator, 72 percent.
Originally based on the best-selling novel by Gregory Maguire &mdash; Wicked tells the untold story of the witches of Oz, with Erivo as Elphaba and Grande as Glinda. Winnie Holzman, the stage production&#39;s book writer, wrote the screenplay for Chu&#39;s movie with Dana Fox. Academy Award-winning composer and lyricist Stephen Schwartz adapted the musical for the screen.
Directed by Ridley Scott, the $250 million Gladiator sequel opens 24 years after the first film and is looks to open to hearty $65 million or thereabouts. The follow-up stars Paul Mescal, <a href="https://www.hollywoodreporter.com/t/denzel-washington/">Denzel Washington</a>, Connie Nielsen and Fred Hechinger, among others.
&nbsp;
<a href="https://www.hollywoodreporter.com/movies/movie-news/gladiator-2-trailer-paul-mescal-1236009553/">The film </a>sees Mescal playing a grown-up Lucius Verus II, a nephew of Emperor Commodus from the original film, played by Joaquin Phoenix. Lucius returns to Rome after being forced into slavery to battle not as a ruler but as a gladiator out for revenge and power, seeking to return the glory of Rome to its people.

CMCSA

IMAX

PARA

"Box Office: 'Wicked' Earns Huge $19M From Week-Long Previews, 'Gladiator II' Soars to $6.5M on Thursday Alone" - Hollywood Reporter

ONDS

Ondas shares are trading higher after the company announced it received a purchase order for the iron drone raider counter-drone system from an Israeli defense company.

INDP

Indaptus Therapeutics shares are trading lower. The company announced a $2.135 million direct offering and private placement.

RBC Capital analyst Deane Dray maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Sector Perform and lowers the price target from $99 to $93.

RBC Capital Maintains Sector Perform on Atkore, Lowers Price Target to $93

Scotiabank analyst Tomas Gonzalez downgrades Enel Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENIC#NYSE">ENIC</a>) from Sector Outperform to Sector Perform and maintains the price target from $3.9 to $3.9.

ENIC

Scotiabank Downgrades Enel Chile to Sector Perform, Maintains Price Target to $3.9

Politics

General

HOOD

Robinhood Chief Legal Officer Dan Gallagher Says Not Interested In Being Considered For The U.S. SEC Chair Role

Although Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is up over 190% year-to-date, &#8220;over the last five months the stock has been relatively flat, leaving bulls and bears at an inflection point,&#8221; <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40652895/exclusive-beyond-the-magnificent-seven-direxions-egilinsky-reveals-top-sector-picks">Direxion&#8216;s Ed Egilinsky says</a>.
This pause in growth signals the stock might be priced to perfection. Some active traders are watching for the next move. 
For those who consider the stock&#8217;s price is perfection and forward expectations are not lofty enough to propel it higher, the Direxion Daily NVDA Bear 1X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>) offers a way to get profit from any expected correction in the stock. 
However, traders who believe the stock will trend higher in the short term, can look to trade the Direxion Daily NVDA Bull 2X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>).
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">Jim Cramer Doubles Down On Nvidia: &#8216;Demand Is Accelerating&#8217; As AI Customers &#8216;Have No Choice&#8217; But To Buy Its Chips</a>
<h2 class="wp-block-heading">Potential R&amp;D Spending Not Baked In</h2>
While Nvidia remains the barometer for the AI space, Egilinsky stresses the importance of continued innovation to retain its competitive edge in AI chips. 
&#8220;This could result in a more sizable commitment to their R&amp;D spending that might not be totally baked into current projections,&#8221; he said.
<h2 class="wp-block-heading">Geopolitical Tensions, Tariffs Could Impact Future Growth</h2>
Beyond its product and performance, Nvidia's future is increasingly shaped by geopolitical risks, particularly the U.S. tariff stance. 
&#8220;Traders will be waiting for a sign to trade the next move in Semis and for short-term traders that can be either a bullish view or bearish sentiment,&#8221; Egilinsky said.
The Donald Trump administration's policies on global trade, especially tariffs, could affect Nvidia's revenue from China and its reliance on Taiwan for chip production.
<h2 class="wp-block-heading">AI Growth Still Promising, But Tariffs Add Uncertainty</h2>
Despite these risks, Nvidia's future looks promising, especially with Blackwell shipments ramping up next quarter. 
One way to gauge Nvidia's AI growth prospects is by looking at its key customers like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). 
These tech giants rely heavily on Nvidia's chips to power their cloud platforms, machine learning, and data centers. As these companies expand their AI operations, Nvidia's role in driving this growth could bolster its position in the market, fueling continued demand for its products.
Egilinsky said the excessive demand for Nvidia&#8217;s products might &#8220;send the stock to new all-time highs.&#8221; Still, the company's ability to navigate geopolitical hurdles will be crucial to sustaining this growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a></li>
</ul>

Long Ideas

AMZN

MSFT

NVDA

NVDD

NVDU

Nvidia 'Bulls And Bears At An Inflection Point,' Expert Says: Will AI Growth Overcome Global Tariff Risks?

<a href="https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395">https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395</a>

'Unilever To Slim Down But Not Spin Off Food Business, Says Chief' - Financial Times

RBC Capital analyst Rishi Jaluria maintains Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) with a Outperform and raises the price target from $32 to $36.

CWAN

RBC Capital Maintains Outperform on Clearwater Analytics Hldg, Raises Price Target to $36

INSM, SINT and POAI are among mid-day movers

SOBR, AWIN among major tech gainers; SMXT, RYDE among losers

Ryde Group Limited Class A (RYDE) has released an update. Ryde Group Ltd, a leading Singapore-based mobility and quick commerce technology platform...

Ryde Group Expands into European Markets

Ryde Group Limited Class A (RYDE) has released an update. Ryde Group Ltd has entered into a consulting agreement to leverage strategic, advisory, a...

Ryde Group Ltd Signs Strategic Consulting Deal

Ryde: Overpriced Ride-Sharing Service Facing Intense Competition

Primega Group Holdings: Another Overvalued Chinese Micro-IPO Poised To Drop

Ryde prices $4.5M public offering

Ryde Group Limited Class A (RYDE) has released an update. Ryde Group Ltd, a Singapore-based technology platform for mobility, has announced a publi...

Ryde Group Launches $4.5 Million Public Offering

Ryde reports 1H results

Ryde Group (RYDE) extended it's strategic partnership with Singlife, "a homegrown financial services company." Building on the RydeSafe initiative ...

Ryde Group expands deal with Singlife on work injury compensation protection

AIRJ

AWIN

CALT

ESLT

INSM

JBDI

MINM

MRAI

NEOV

OBLG

PEGY

PGHL

POAI

RDZN

SINT

SMMT

SMXT

SOBR

STSS

UBXG

UEIC

VHAI

Press Releases

Ryde Unveils 7 Driver Commitments to Build a Fairer Platform

Ryde Takes Center Court with Tennis Star Sarah Pang Joining Ryde Empowers!

Ryde and Singlife Forge Strategic Partnership That Protects Passengers Beyond Rides

Ryde Group Ltd Addresses Share Price Volatility, Reaffirms Strong Business Fundamentals

Ryde Announces Pricing of $4.5 Million Public Offering

Ryde Announces Closing of $4.5 Million Public Offering

Ryde Launches REMA 2024: A Commitment To Educational Excellence For Driver-Partners' Children

Ryde Reports First Half 2024 Results, Positions for Accelerate Growth

Ryde Opens Doors to International Travelers, Offering Seamless Mobility Solutions in Singapore

Ryde Extends Partnership with Singlife to Implement Work Injury Compensation Protection for Driver-Partners

Comments

Ryde Group

Ryde Group (RYDE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga